{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:26:44Z","timestamp":1790821604723,"version":"4.1.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    CD101 is a novel echinocandin with concentration-dependent fungicidal activity\n                    <jats:italic>in vitro<\/jats:italic>\n                    and a long half-life (\u223c133 h in humans, \u223c70 to 80 h in mice). Given these characteristics, it is likely that the shape of the CD101 exposure (i.e., the time course of CD101 concentrations) influences efficacy. To test this hypothesis, doses which produce the same total area under the concentration-time curve (AUC) were administered to groups of neutropenic ICR mice infected with\n                    <jats:named-content content-type=\"genus-species\">Candida albicans<\/jats:named-content>\n                    R303 using three different schedules. A total CD101 dose of 2 mg\/kg was administered as a single intravenous (i.v.) dose or in equal divided doses of either 1 mg\/kg twice weekly or 0.29 mg\/kg\/day over 7 days. The studies were performed using a murine disseminated candidiasis model. Animals were euthanized at 168 h following the start of treatment. Fungi grew well in the no-treatment control group and showed variable changes in fungal density in the treatment groups. When the CD101 AUC from 0 to 168 h (AUC\n                    <jats:sub>0\u2013168<\/jats:sub>\n                    ) was administered as a single dose, a &gt;2 log\n                    <jats:sub>10<\/jats:sub>\n                    CFU reduction from the baseline at 168 h was observed. When twice-weekly and daily regimens with similar AUC values were administered, net fungal stasis and a &gt;1 log\n                    <jats:sub>10<\/jats:sub>\n                    CFU increase from the baseline were observed, respectively. These data support the hypothesis that the shape of the CD101 AUC influences efficacy. Thus, CD101 administered once per week demonstrated a greater degree of fungal killing than the same dose divided into twice-weekly or daily regimens.\n                  <\/jats:p>","DOI":"10.1128\/aac.00758-17","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T20:30:26Z","timestamp":1503952226000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters"],"prefix":"10.1128","volume":"61","author":[{"given":"Elizabeth A.","family":"Lakota","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics (ICPD), Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Bader","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics (ICPD), Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon","family":"Ong","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bartizal","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Miesel","sequence":"additional","affiliation":[{"name":"Eurofins Panlabs, Ltd., St. Charles, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Andes","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2014Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics (ICPD), Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics (ICPD), Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics (ICPD), Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lepak","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2014Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3400.3400"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01626-16"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_3_1_7_2","unstructured":"Pfizer Inc. 2016. Eraxis injection package insert. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea. Accessed 22 February 2017."},{"key":"e_1_3_1_8_2","unstructured":"Merck Sharp & Dohme Corp. 2017. Cancidas injection package insert. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c\n. Accessed 22 February 2017."},{"key":"e_1_3_1_9_2","unstructured":"Astellas Pharma US Inc. 2016. Mycamine injection package insert. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf\n. Accessed 22 February 2017."},{"key":"e_1_3_1_10_2","unstructured":"Hall\nD ShinabargerDL PillarCM. 2015. Evaluation of the fungicidal activity of CD101 a novel echinocandin and comparators against recent clinical isolates of Candida spp. Abstr 55th Intersci Conf Antimicrob Agents Chemother abstr M-825."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq081"},{"key":"e_1_3_1_12_2","unstructured":"The Medicines Company. 2016. Orbactiv injection package insert. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=085d6d1a-21c2-11e4-8c21-0800200c9a66."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis001"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-11"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp126"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01337-06"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ715"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-07"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/653057"},{"key":"e_1_3_1_21_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"NCCLS","year":"2008","unstructured":"NCCLS. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. Document M27-A3. NCCLS, Wayne, PA."},{"key":"e_1_3_1_22_2","volume-title":"S-ADAPT\/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic and population data analysis","author":"Bauer RJ","year":"2006","unstructured":"Bauer RJ . 2006. S-ADAPT\/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Los Angeles, CA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00758-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00758-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:42:20Z","timestamp":1645458140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00758-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1128\/AAC.00758-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00758-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00758-17"}}